Chemed Q2 adj. EPS $4.60 (+4.3% YoY); Roto-Rooter revenue +26.1%; full-year guidance raised to $18.20-$18.50

CHEMED CORP

2021-Q2 EPS reported $7.52 revenue$1,059,616,000

Consolidated revenue $532M (+6.0%); GAAP diluted EPS $3.51 (-29.9%); adjusted diluted EPS $4.60 (+4.3%).
VITAS net patient revenue $312M (-4.7%); ADC 17,995 (-6.3%); adjusted EBITDA margin ex-Medicare Cap 17.4% (-430bps).
Roto-Rooter revenue $220M (+26.1%); adjusted EBITDA margin 29.2% (+236bps); residential +23.7%, commercial +31.8%.
Full-year 2021 adjusted EPS guidance raised to $18.20-$18.50 from prior $17.00-$17.50; no debt, $92M cash.
Company repurchased 250,000 shares for $122M during Q2; $312M remaining authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.